Latest Articles

Publication Date
Imaging of Thoracic Manifestations of Obstetric and Gynecologic Disease.

Cardiothoracic involvement by obstetric and gynecologic pathologic conditions creates a broad spectrum of clinical and radiologic manifestations, ranging from mild to critical. The authors describe the unique and often unrecognized …

Published: July 31, 2026, midnight
p53-mediated epigenetic regulation in the pathogenesis of endometriosis.

Endometriosis (EMs) is a common gynecological disorder affecting reproductive‑aged women, characterized by ectopic endometrial growth and chronic pelvic pain that severely impairs quality of life. Although its pathogenesis remains incompletely …

Published: July 21, 2026, midnight
Ovarian endometriosis associated with significantly elevated CA19-9: a case report.

Carbohydrate antigen 19-9 (CA19-9) is a well-established tumour marker primarily associated with pancreaticobiliary and gastrointestinal malignancies. Its elevation in benign gynaecological conditions, particularly in isolated ovarian endometriosis (OE) without malignancy, …

Published: July 21, 2026, midnight
Somatic Cancer Driver Mutation Analysis in Endometriosis with Tumor-like Presentations: A Case Series Study.

Background/Objectives: Endometriosis manifests as ectopic endometrial tissue outside the uterine cavity. This lesion can sometimes appear at unusual anatomical sites or within the intestinal tract, growing and mimicking cancer. Such …

Published: July 20, 2026, midnight
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Beyond growing teratoma syndrome: post-treatment manifestations and diagnostic challenges following ovarian immature teratoma.

Growing teratoma syndrome (GTS) is a rare condition classically associated with platinum-based chemotherapy for malignant ovarian germ cell tumors. However, post-treatment findings following ovarian immature teratoma may represent a broader …

Published: July 14, 2026, midnight
The role of tumor necrosis factor alpha in regulating CYFRA 21-1 as a potential biomarker for endometriosis: A cross-sectional study.

Background: Endometriosis is one of the most common gynecological conditions, and the gold standard for its diagnosis is laparoscopy. Cytokeratin fragment 21-1 (CYFRA 21-1) has emerged as a potential biomarker …

Published: July 14, 2026, midnight
Abdominal Wall Endometriosis in Appendectomy Scar 42 Years After Initial Surgical Procedure-Case Report and Literature Review.

Background and Clinical Significance: Abdominal wall endometriosis (AWE) is an ectopic endometrial tissue embedded into the anterior abdominal wall, mainly infiltrating the rectus abdominis or oblique muscles and subcutaneous tissue. …

Published: July 9, 2026, midnight
When the appendix hides: the radiologist's guide to appendix variants and mimics.

The identification of the appendix often presents a diagnostic challenge due to its significant anatomical variability, compounded by the frequency with which appendiceal pathologies manifest as atypical clinical presentations that …

Published: July 6, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!